ライフサイエンスコーパス: IOP

1 IOP elevation in Brown Norway rats showed a trend toward

2 IOP in the NMS group was significantly higher than in th

3 IOP reduction was greater in subjects treated with oral

4 IOP values did not differ between the MCD (11.25 +/- 1.6

5 IOP was measured three times using a Nidek NT-510 non-co

6 IOP was obtained at 8:00 am, 10:00 am, and 4:00 pm on da

7 IOP, corneal status, and endothelial cell count values w

8 IOP-lowering drops were prescribed for 30 cases (7.2%).

9 the procedure were mild inflammation (13%), IOP spikes (6%), hyphema, corneal edema, and BCVA loss (

10 We used a validated IOP PRS derived from 146 IOP-associated variants in a linear regression model adj

11 s required glaucoma surgery with 2.2 +/- 1.2 IOP-lowering surgeries per eye.

12 14 mm Hg and 21 mm Hg with and without a 20% IOP reduction from baseline, median IOP, medications, ri

13 these eyes, only 26.6% of eyes achieved >20% IOP reduction at 3 months compared with baseline.

14 We defined success as >=20% IOP reduction or >=1 medication reduction without an IOP

15 s all diagnostic pairings for 2015 (3 of 23: IOP, pattern standard deviation, and 7-o'clock RNFL thic

16 n curve (DTC) 1 week before the TSST, with 3 IOP measurements performed between 8:00 am and 2:00 pm.

17 EyeMate were requested to obtain at least 4 IOP measurements daily.

18 Overall, 92 860 IOP measurements over 15 811 measurement days were obtai

19 Absolute IOP reduction at 2 months was greater after initial SLT

20 No significant difference in early absolute IOP reduction at 2 months after repeat SLT was noted bet

21 halmic examination, including visual acuity, IOP, slit lamp examination, and dilated funduscopy as we

22 HP was successfully managed with additional IOP-lowering medications in a majority of cases and did

23 One year after 3 administrations, IOP was controlled in most subjects without additional t

24 laucoma, and corneal abnormalities affecting IOP measurement.

25 of the subjects in the TSST group showed an IOP increase higher than 2 mmHg after the test compared

26 The subgroup of patients with an IOP elevation >=2 mmHg had a significantly higher VF tes

27 ction or >=1 medication reduction without an IOP lowering procedure.

28 ithin 30 days, recovery of anatomy, BVA, and IOP occurred sooner (P < .05).

29 se relationship between LOXL1 expression and IOP, which worsened with age.

30 ect of ICP elevation on outflow facility and IOP is blocked by TTX.

31 Mean baseline IOP was 19.8+/-7.4 mmHg and IOP reduction was 22.7%, 20.2%, 20.7%, and 23.7% at post

32 wept-source optical coherence tomography and IOP was estimated by the new-generation tonometer Corvis

33 (IOP), the active substances of the applied IOP-lowering drugs, the best corrected visual acuity (BC

34 Refractory glaucoma was defined as IOP >21 mmHg on maximum tolerated glaucoma medications o

35 demographics, glaucoma status, and baseline IOP.

36 s no significant difference between baseline IOP and any subsequent visit.

37 uccess (hazard ratio [HR], 0.67 for baseline IOP >21 mmHg vs. <=21 mmHg, 95% CI, 0.57-0.80; P < 0.001

38 end points were IOP and change from baseline IOP through week 12.

39 for age, gender, type of glaucoma, baseline IOP, and number and type of glaucoma medications.

40 % CI, 1.02-2.50; P = 0.041), higher baseline IOP (HR, 1.07 per mmHg; 95% CI, 1.02-1.12; P = 0.008), a

41 Patients with higher baseline IOP had increasingly higher odds of achieving reduction

42 ogistic regression analysis, higher baseline IOP predicted higher odds of POD1 IOP spike >40 mmHg, wh

43 Higher baseline IOP was strongly associated with treatment success (haza

44 Mean baseline IOP was 19.8+/-7.4 mmHg and IOP reduction was 22.7%, 20.

45 % mean IOP reduction at POM 12 when baseline IOP was more than 21 mmHg and 20.1% when it was 21 mmHg

46 9% overall and 68.8% for those with baseline IOP >24 mm Hg.

47 mmHg or reduced less than 20% from baseline, IOP of 5 mmHg or less, reoperation for glaucoma, or loss

48 rix-augmented AGV surgery may provide better IOP control in the intermediate postoperative period and

49 Associations between IOP lowering after CE and biometric parameters may allow

50 pling rates and duty cycles, to characterize IOP dynamics.

51 ntly after accounting for a recent in-clinic IOP measured by Goldmann applanation tonometry.

52 mann-correlated IOP, and corneal-compensated IOP.

53 nd 1896 receiving ranibizumab) with complete IOP data from 3032 patients with 12 months of follow-up

54 of eyes at 1-year with (1) no 2 consecutive IOP readings >17 mm Hg or clinical hypotony without (com

55 cope and widefield visualisation, continuous IOP control and drainage of sub-retinal fluid without th

56 ed acute hydrops after medically controlling IOP in 1 eye before the scheduled surgery.

57 RF), corneal hysteresis, Goldmann-correlated IOP, and corneal-compensated IOP.

58 d (2) at least a 20% reduction from decision IOP.

59 onade after PPV to treat retinal detachment, IOP increased significantly in patients who received 500

60 Mean +/- standard deviation IOP was 14.0+/-4.2 mmHg in the tube group and 12.1+/-4.8

61 r (IO) pressure transducers, using different IOP sampling rates and duty cycles, to characterize IOP

62 Least squares mean diurnal IOP (+/- standard error) at month 12 was 16.2 +/- 0.23 m

63 with open-angle glaucoma provides effective IOP reduction or sustained IOP control and meaningful me

64 an Mgp.TMcKO mouse which developed elevated IOP.

65 ctures, but 8 eyes (4 patients) had elevated IOP (44.4%).

66 Among these 9 eyes, 5 eyes had elevated IOP, and 4 of these 5 eyes had IOP >30 mm Hg.

67 urgery lowered the risk of markedly elevated IOP in the early postoperative period in patients with g

68 gh the investigated patients showed elevated IOP and at least 1 additional glaucoma risk factor (i.e.

69 isk prediction of susceptibility to elevated IOP that may not be apparent during in-clinic hours, req

70 strongest genetic predisposition to elevated IOP, greater caffeine consumption was associated with hi

71 Numerical trends suggesting fewer IOP elevations with EGP-437, similar efficacy overall, a

72 yes (10.6%) required repeat intervention for IOP control with median time of 3.17 years (IQR, 0.92-6.

73 mal improvement was significantly longer for IOP and BVA than anatomy (P < .001).

74 as a key IOP-sensing mechanism necessary for IOP homeostasis.

75 nd secondary measures were survival rate for IOP control, glaucoma medication use, complication rate,

76 l outflow pathway structures responsible for IOP homeostasis.

77 degeneration, supporting a damaging role for IOP-induced mTOR activation in perturbing metabolism and

78 Qualified success for IOP <= 21 mmHg at 1 year was 82.6% and 81% over 10 years

79 Eyes needing repeat surgery for IOP control were considered as failures.

80 1 year was 82.6% and 81% over 10 years; for IOP <= 16 mmHg, it was 81.4% at 1 year and decreased to

81 Repeat SLT maintained drop-free IOP control in 67% of 115 eyes at 18 months, with no cli

82 Hg) and -1.8 mmHg (-4 to 0.2 mmHg) for a GAT IOP <=21 mmHg and >21 mmHg, respectively.

83 However, for every 1-mmHg increase in GAT IOP, the difference between the 2 tonometers increased b

84 The GAT IOP ranged from 6 to 50 mmHg with a mean IOP of 19.5 +/-

85 large cohort of eyes undergoing SLT, greater IOP and angle pigment before SLT correlated positively w

86 nic anhydrase inhibitors may lead to greater IOP reduction.

87 had elevated IOP, and 4 of these 5 eyes had IOP >30 mm Hg.

88 s that had fast progression, 41% of them had IOP <21 mmHg in all visits during follow-up, whereas 20%

89 nt with non-linear changes in cornea at high IOP.

90 Patients with diabetes, higher IOP, and more severe VF loss at baseline were at higher

91 Bilateral disease, higher IOP, and disc hemorrhage were confirmed as risk factors

92 showed a statistically significantly higher IOP by 0.92 mmHg (95% confidence interval [CI], 0.88-0.9

93 and whether genetic predisposition to higher IOP modified these associations.

94 feine consumption was associated with higher IOP and higher glaucoma prevalence.

95 Eyes in the highest IOP PRS quintile showed an early morning IOP increase of

96 ned from the pump flow rate required to hold IOP at different levels.

97 morning IOP than the maximum in-office hours IOP.

98 e aqueous humor outflow to provide immediate IOP reduction, prevent post-operative hypotony, and pote

99 ay guide additional interventions to improve IOP control.

100 s implemented for the technicians to improve IOP measurement agreement with physicians.

101 al intervention did not improve agreement in IOP measurements between technicians and physicians.

102 The primary outcome was the mean change in IOP (in millimeters of mercury) at 12 months.

103 The change in IOP following washout for patients using 0 (n = 100), 1

104 erent between treatment groups but change in IOP from baseline was lower in the sponge vs the injecti

105 The average change in IOP was 0.15 +/- 1.82 mmHg.

106 ol group did not show significant changes in IOP, heart rate, salivary cortisol levels, and STAI scor

107 At 3 weeks, a significant decrease in IOP was seen in Group 1 (20.16 +/- 3.3 to 15.05 +/- 2.4m

108 show a clinically significant difference in IOP-lowering effect or tolerability.

109 pse when challenged with acute elevations in IOP, suggesting elevated episcleral venous pressure (EVP

110 The time to maximal improvement in IOP and BVA may be longer than the time to anatomic reso

111 A greater increase in IOP from baseline to 2 weeks was observed in the prednis

112 I], 1.4-7.3; P = 0.005) and mean increase in IOP outside office hours of 2.7 mmHg (95% CI, 0.61-4.7;

113 surgery resulted in a transient reduction in IOP at postoperative week 1.

114 The reduction in IOP was significant only at postoperative week 1 (P = 0.

115 singly higher odds of achieving reduction in IOP.

116 prost implant were noninferior to timolol in IOP lowering after each administration.

117 lar period was defined as the variability in IOP measurements obtained during that period on differen

118 ative changes in outcome measures, including IOP and medication use, were assessed.

119 ant reduction in the risk of steroid-induced IOP elevation after corneal transplantation relative to

120 VF testing does not influence IOP as measured with a non-contact tonometer.

121 While BIRB 796 did not influence IOP, treatment over four weeks in rats prevented degrada

122 of shear-mediated SC mechanobiology as a key IOP-sensing mechanism necessary for IOP homeostasis.

123 mption was associated with a 0.10-mmHg lower IOP (P(trend) = 0.01).

124 deling showed that choroidal thinning, lower IOP change, and lower corneal hysteresis were significan

125 the use of both GDDs is justifiable to lower IOP when more conservative management has failed.

126 eine intake was associated weakly with lower IOP: the highest (>=232 mg/day) versus lowest (<87 mg/da

127 by death of retinal ganglion cells; lowering IOP is the only proven treatment strategy to delay disea

128 e MGI was noninferior to the BGI in lowering IOP.

129 lts indicate that Tafluprost not only lowers IOP, but may also enhance retinal blood flow in POAG pat

130 P PRS was correlated positively with maximum IOP, disease severity, need for surgery, and number of a

131 Mean IOP decreased in all treatment groups during the 12 mont

132 Mean IOP did not change from baseline to final visit in the o

133 Mean IOP did not change significantly from baseline to 12 and

134 Mean IOP was reduced in group 1 (21.8 to 15.6 mmHg, P < 0.000

135 groups in surgical success (P = .357), mean IOP (P = .707), number of glaucoma medications (P = 1.00

136 n IOP stratification demonstrated 30.5% mean IOP reduction at POM 12 when baseline IOP was more than

137 GAT IOP ranged from 6 to 50 mmHg with a mean IOP of 19.5 +/- 8.8 mmHg.

138 Additional mean IOP reduction of 16.4% (P < 0.0001) was achieved with ea

139 Hg above baseline, unmedicated IOP, and mean IOP were analyzed as secondary outcomes.

140 laser power stratification demonstrated mean IOP reduction of 31.5% at POM 12 with laser power of 250

141 he AGV group had a significantly higher mean IOP before phacoemulsification than the BGI group (P = 0

142 Each 1 mmHg higher mean IOP was associated with 0.05 mum/year faster RNFL loss (

143 The overall mean IOP change was -0.5 mmHg (95% confidence interval CI, -0

144 The mean IOP decreased from 20.8 +/- 6.8 mmHg to 16.2 +/- 2.8 mmH

145 At postoperative month 24, the mean IOP was 12.6 +/- 4.4 mmHg (n = 29, P = 0.519) on 2.0 +/-

146 At final follow-up, mean IOP (12.6 +/- 3.8 mmHg, median 11.8 mmHg, 7-19 mmHg) in

147 ut a 20% IOP reduction from baseline, median IOP, medications, risk factors for failure, intervention

148 owing at 2 consecutive visits: IOP >21 mmHg, IOP reduction <20% from baseline, or increase in glaucom

149 est IOP PRS quintile showed an early morning IOP increase of 4.3 mmHg (95% confidence interval [CI],

150 e 5.4-fold more likely to show early morning IOP spikes than the lowest quintile (odds ratio 95% CI,

151 Early morning IOP spikes were defined by a higher early morning IOP th

152 pikes were defined by a higher early morning IOP than the maximum in-office hours IOP.

153 al blood flow in POAG patients with a normal IOP.

154 hus, LOXL1 expression is required for normal IOP control, while ablation results in altered ECM repai

155 d to surgically treated patients with normal IOP (n = 22) using optical coherence tomography angiogra

156 macular region of POAG patients with normal IOP treated with topical Tafluprost (n = 20) compared to

157 ach to restoring TM function and normalizing IOP, human adipose-derived stem cells (ADSCs) were induc

158 ces showed the greatest success in obtaining IOP control.

159 abeculotomy is highly effective in obtaining IOP control; however, complete canalization of Schlemm's

160 Significant elevations of IOP, salivary cortisol, STAI scores, and heart rate occu

161 We measure both as a function of IOP in ex vivo porcine cornea, obtaining values consiste

162 Incidence of IOP increase >10 mmHg above baseline, unmedicated IOP, a

163 The incidence of IOP increase >=10 mmHg relative to baseline on POD1 was

164 On POD1, the incidence of IOP spike >40 mmHg was significantly higher at 14.4% in

165 ical trial cohorts exhibit similar levels of IOP elevation upon washout, using standardized methodolo

166 , and disease progression via maintenance of IOP control.

167 for continual and long-term measurements of IOP.

168 eyes suffering from POAG, IOP and number of IOP-lowering drugs applied can be effectively reduced by

169 After surgery, IOP and the number of IOP-lowering medications decreased significantly by 42.3

170 All eyes were washed out of IOP-lowering medications before surgery and remained unm

171 up had a significantly greater percentage of IOP reduction compared with the closed group (43.1% vs.

172 The rate of IOP elevation was 14% with netarsudil and 21% with place

173 re was defined as less than 20% reduction of IOP from medicated baseline or IOP >21 mmHg at 2 consecu

174 r organisms used for experimental studies of IOP dynamics and glaucoma: cynomolgus macaque (Macaca fa

175 n deviation (P = 1.00), or concurrent use of IOP-lowering medication (P = 0.52).

176 r in animals exposed to 2, 4, and 9 weeks of IOP elevation.

177 d 25% success rate with 1.7 +/- 1.9 years of IOP control.

178 Analysis based on IOP stratification demonstrated 30.5% mean IOP reduction

179 tial causal effects of coffee consumption on IOP.

180 upport a causal effect of coffee drinking on IOP (P > 0.1).

181 ariate analysis, no effect of the VF test on IOP was found (global model fit R(2) = 0.12), whether ba

182 reduction of IOP from medicated baseline or IOP >21 mmHg at 2 consecutive visits at postoperative mo

183 incisional surgeries, <3 glaucoma drops, or IOP <=30 mm Hg (P < .05).

184 teristics significantly predicted success or IOP spikes.

185 ad no association with procedural success or IOP spikes.

186 bserved between fundus abnormalities, VA, or IOP with hematologic parameters (P > 0.05).

187 ata (including complications), and outcomes (IOP and VA) were entered in a secure online database.

188 and HP was seen in 64 eyes (32%) with a peak IOP (mean +/- SD) of 29.6 +/- 7.8 mm Hg and peak inciden

189 As in eyes suffering from POAG, IOP and number of IOP-lowering drugs applied can be effe

190 r baseline IOP predicted higher odds of POD1 IOP spike >40 mmHg, whereas the presence of HMS was asso

191 Postinjection IOP elevation, injection frequency, and total number of

192 had longer time to failure for postoperative IOP control vs fornix-based incision.

193 21.0 mmHg or more showed mean postoperative IOP reduction ranging from -6.2 to -6.9 mmHg.

194 Mean postoperative IOP was not significantly different between treatment gr

195 m Hg, mean 30.9 mm Hg); median postoperative IOP was 18 mm Hg (range 5-40 mm Hg, mean 20.3 mm Hg].

196 ted with a lower likelihood of postoperative IOP spike.

197 The primary outcomes were postoperative IOP and requirement of pressure-lowering medications.

198 ence not entirely explained by posttreatment IOP elevation.

199 No difference in postwashout IOP change was detected among individual prostaglandin a

200 characteristics, including age, preoperative IOP, preoperative glaucoma medications, and previous gla

201 ge of 46.94 +/- 11.81 years and preoperative IOP of 27.70 +/- 10.30 mmHg taking 3.73 +/- 0.98 glaucom

202 Higher preoperative IOP (5 mmHg increase; HR, 1.2; P = 0.038) and younger ag

203 hances survival, whereas higher preoperative IOP and postoperative maneuvers are predictors of increa

204 Mean preoperative IOP decreased from 20.4 +/- 5.3 mmHg to 14.8 +/- 3.0 mmH

205 The mean preoperative IOP for all patients was 15.2 mmHg (standard deviation [

206 Median preoperative IOP was 30 mm Hg (range 18-49 mm Hg, mean 30.9 mm Hg); m

207 emulsification in patients with preoperative IOP of less than 20 mmHg.

208 he AADI was defined as intraocular pressure (IOP) >18 mm Hg or not reduced by 30% below baseline on 2

209 ta of patients who had intraocular pressure (IOP) <=21 mm Hg at 6 weeks (ie, the time at which the tu

210 llow-up, and medicated intraocular pressure (IOP) <=36 mmHg on <=4 medications preoperatively.

211 Visual acuity (VA), intraocular pressure (IOP) and complications associated with the follow up per

212 l caffeine intake with intraocular pressure (IOP) and glaucoma and whether genetic predisposition to

213 come measures included intraocular pressure (IOP) and number of antiglaucoma medications after 6 week

214 amage and elevation of intraocular pressure (IOP) are poorly understood.

215 that measures habitual intraocular pressure (IOP) at any given time and promises to revolutionize the

216 Success was defined as intraocular pressure (IOP) between 6 and 21 mmHg (criterion A) or between 6 an

217 the eye, resulting in intraocular pressure (IOP) changes that are variable in magnitude and time cou

218 been linked to lowered intraocular pressure (IOP) in patients with glaucoma, ocular hypertension, ana

219 field (VF) testing on intraocular pressure (IOP) in patients with ocular hypertension (OHT) or glauc

220 Postoperative intraocular pressure (IOP) less than or equal to 24 mm Hg with or without medi

221 res were postoperative intraocular pressure (IOP) level and secondary measures were survival rate for

222 glaucoma surgeries on intraocular pressure (IOP) management in ARS.

223 l thickness influences intraocular pressure (IOP) measurement.

224 Elevated intraocular pressure (IOP) narrows Schlemm's canal (SC), theoretically increas

225 al failure, defined as intraocular pressure (IOP) of more than 21 mmHg or reduced less than 20% from

226 en cases (2.6%) had an intraocular pressure (IOP) over 30 mm Hg at POD1.

227 Intraocular pressure (IOP) readings were obtained by Goldmann applanation tono

228 Intraocular pressure (IOP) reduction prevents development of glaucoma and visi

229 Increased intraocular pressure (IOP) represents a major risk factor for glaucoma, a prev

230 Icare(R) HOME allows intraocular pressure (IOP) sampling by the patient.

231 tion of an implantable intraocular pressure (IOP) sensor in patients with primary open angle glaucoma

232 Three intraocular pressure (IOP) success cutoffs were defined: 18 mmHg or less and 2

233 The mean intraocular pressure (IOP) was 14.88 +/- 3.34 (6-25) mmHg.

234 Intraocular pressure (IOP) was lowered surgically in 2 infants and medically i

235 Intraocular pressure (IOP) was measured using a Goldmann applanation tonometer

236 Intraocular pressure (IOP) was similar for both study groups at month 36 (mean

237 elivered, and baseline intraocular pressure (IOP) with success.

238 tissue that maintains intraocular pressure (IOP) within a physiologic range.

239 Intraocular pressure (IOP), best corrected visual acuity (BCVA) logMAR and num

240 tified, including age, intraocular pressure (IOP), central corneal thickness (CCT), optic nerve head

241 visual acuity (BCVA), intraocular pressure (IOP), clinical presentation, eye culture results, and tr

242 ontinual monitoring of intraocular pressure (IOP), composed of an intraocular sensor, and a hand-held

243 injection elevation of intraocular pressure (IOP), injection frequency, and number of injections were

244 The intraocular pressure (IOP), the active substances of the applied IOP-lowering

245 milar in terms of mean intraocular pressure (IOP), the proportion of eyes meeting target IOP, and cha

246 ome measures including intraocular pressure (IOP), use of glaucoma medications, visual acuity, and co

247 a as indicated by high intraocular pressure (IOP), worsening visual field, or optic nerve head change

248 udies characterized an intraocular pressure (IOP)-dependent decline in retinal pyruvate levels couple

249 Pretreatment IOP before initial SLT was significantly higher than bef

250 ent with PCG may be at risk of sudden raised IOP resulting in acute hydrops, and early treatment may

251 Glaucoma surgeries reduce IOP by facilitating aqueous humor outflow through a vent

252 Surgeons should expect to reduce IOP approximately 1 to 2 mmHg with phacoemulsification i

253 gery seems to be cost effective for reducing IOP in patients with mild to moderate OAG versus catarac

254 n 6 and 18 mmHg (criterion B) and a relative IOP reduction of 20% or more compared with baseline.

255 significantly higher than before retreatment IOP of repeat SLT (mean difference, 3.4 mmHg; 95% confid

256 Effect of age, sex, IOP, central corneal thickness (CCT) and AXL, disc area,

257 r LPI, more prednisolone-treated eyes showed IOP elevation of 6 to 15 mmHg as compared with nepafenac

258 (6 eyes vs. 1 eye; P = 0.04); no eyes showed IOP elevation of more than 15 mmHg.

259 F inhibitors, whereas clinically significant IOP elevations occurred in a small proportion of eyes.

260 as the proportions of clinically significant IOP increases were 5.6% and 8.8%, respectively.

261 pair are relatively uncommon and were solely IOP related in this patient group.

262 Eyes with stricter IOP control over follow-up visits had a smaller chance o

263 Mean sitting and supine IOPs were 15.3+/-3.5 mmHg and 15.9+/-3.7 mmHg, respectiv

264 After surgery, IOP and the number of IOP-lowering medications decreased

265 rovides effective IOP reduction or sustained IOP control and meaningful medication reduction for up t

266 t surgery was more likely to yield sustained IOP reduction for patients with primary open-angle glauc

267 as achieving a previously determined target IOP regardless of (qualified success) or without (comple

268 (IOP), the proportion of eyes meeting target IOP, and change in visual acuity since the original trab

269 and potentially offer significant, long-term IOP reduction.

270 The IOP PRS was correlated positively with maximum IOP, dise

271 The IOP was significantly higher in the IN group (17.5 +/- 7

272 type C57BL/6J mice and further amplified the IOP in constitutively active EDA mice.

273 The mean difference (95% LoA) between the IOP measurement of GAT and Icare ic200 was -1 mmHg (-3 t

274 - 2.67 mm Hg) groups (P = .95); however, the IOP values for both of these groups differed significant

275 t, a prostaglandin analogue which lowers the IOP, has shown to also improve the retinal blood flow in

276 t seems to have no negative influence on the IOP lowering-effect of iStent inject(R) implantation in

277 our study, the Icare ic200 overestimated the IOP.

278 These IOP sensors are a prime example that IOL technology will

279 to higher coffee consumption was related to IOP.

280 lems may persist, especially with respect to IOP control.

281 story of SLT may predict reduced response to IOP lowering medications.

282 hourly transient IOP impulse, and transient IOP fluctuation frequency and magnitude between systems

283 ssed the differences in the hourly transient IOP impulse, and transient IOP fluctuation frequency and

284 The mechanism underlying IOP elevation associated with intravitreal injections is

285 mpared with the sham-treated group underwent IOP-lowering surgery (5.7% vs. 11.9%).

286 ncrease >10 mmHg above baseline, unmedicated IOP, and mean IOP were analyzed as secondary outcomes.

287 in the original study required an untreated IOP of 22 mmHg or more and 1 or more risk factors for gl

288 Complete success was 75.6% for an upper IOP cut-off of 14 mm Hg and 76.9% for 21 mm Hg, and qual

289 Secondary outcomes included upper IOP thresholds of 14 mm Hg and 21 mm Hg with and without

290 We used a validated IOP PRS derived from 146 IOP-associated variants in a li

291 ny of the following at 2 consecutive visits: IOP >21 mmHg, IOP reduction <20% from baseline, or incre

292 +0.6 mmHg; P = 0.004), although at 4 weeks, IOP was not significantly different than baseline in eit

293 Primary end points were IOP and change from baseline IOP through week 12.

294 ted multivariable-adjusted associations with IOP using linear regression and with glaucoma using logi

295 ion of phacoemulsification for cataract with IOP reduction was lower than in past referral-based stud

296 Sixty POAG patients with IOP >=21 mm Hg taking maximal topical medication and sch

297 Patients with IOP of 21.0 mmHg or more showed mean postoperative IOP r

298 mHg, but only 9% of them had all visits with IOP <15 mmHg.

299 -up, whereas 20% of them had all visits with IOP <18 mmHg, but only 9% of them had all visits with IO

300 At 1 year, IOP decreased from 27.70 +/- 10.30 mmHg before surgery t